TY - JOUR AU - Ho, Won Jin AU - Jaffee, Elizabeth M. T1 - Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors PY - 2020/01/02/ AB - Pancreatic ductal adenocarcinomas (PDACs) are classically immunologically cold tumors that have failed to demonstrate a significant response to immunotherapeutic strategies. This feature is attributed to both the immunosuppressive tumor microenvironment (TME) and limited immune cell access due to the surrounding stromal barrier, a histological hallmark of PDACs. In this issue of the JCI, Sharma et al. employ a broad glutamine antagonist, 6-diazo-5-oxo-l-norleucine (DON), to target a metabolic program that underlies both PDAC growth and hyaluronan production. Their findings describe an approach to converting the PDAC TME into a hot TME, thereby empowering immunotherapeutic strategies such as anti-PD1 therapy. JF - The Journal of Clinical Investigation JA - J Clin Invest SN - 0021-9738 DO - 10.1172/JCI133685 VL - 130 IS - 1 UR - https://doi.org/10.1172/JCI133685 SP - 71 EP - 73 PB - The American Society for Clinical Investigation ER -